Combining therapies to improve treatment for chronic lymphocytic leukemia
A combination strategy to target pathophysiology of chronic lymphocytic leukemia
This study is looking at a new way to treat chronic lymphocytic leukemia (CLL) by using a mix of medicines that target how CLL cells survive, and it’s for patients who want to explore better treatment options.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10767317 on NIH RePORTER |
What this research studies
This research investigates a combination of therapies targeting the survival mechanisms of chronic lymphocytic leukemia (CLL) cells. It focuses on the B-cell receptor (BCR) signaling pathway and the role of specific proteins that help CLL cells survive. By using a combination of Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 antagonists, the research aims to enhance treatment effectiveness and potentially lead to better patient outcomes. Patients may be involved in clinical trials assessing the safety and efficacy of these combined therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with chronic lymphocytic leukemia who may not have responded adequately to existing therapies.
Not a fit: Patients with other types of blood cancers or those who have not been diagnosed with chronic lymphocytic leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and potentially higher remission rates for patients with chronic lymphocytic leukemia.
How similar studies have performed: Previous research has shown promising results with similar combination therapies in treating chronic lymphocytic leukemia, indicating a potential for success in this approach.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Gandhi, Varsha — University of Tx Md Anderson Can Ctr
- Study coordinator: Gandhi, Varsha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.